| Volume: | |
| Day Range: | |
| Last Trade Time: |
|
Followers
|
41
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2182
|
|
Created
|
01/16/14
|
Type
|
Free
|
| Moderators | |||
_1.jpg)
Benitec Biopharma’s pipeline of in-house and partnered programs to develop therapeutics for chronic and life-threatening conditions is based on our proprietary technology, DNA-directed RNA(ddRNAi). View our out-licensed programs
Due to its demonstrated ability to effect long-lasting gene silencing, once proven in human trials, ddRNAi technology has significant potential to treat or cure a broad range of human diseases and conditions. These include cancers, neurological diseases, infectious diseases, autoimmune diseases, genetic diseases and other afflictions that are associated with the expression of a small number of key genes.
Our in-house pipeline is summarized below, In-house pipeline
. View our out-licensed programs Out-licensed programs Successful development of therapeutic products in just one of these programs would be a major breakthrough in medical therapy.
Tacere Therapeutics develops human therapeutics based on RNA interference (RNAi) and ddRNAi gene-silencing technology from Benitec Biopharma. Using this approach, the drugs we create promise long term treatment or cure with a single dose.
We target human diseases for which there is currently no effective treatment. Our pipeline includes drugs for Hepatitis C and Age-Related Macular Degeneration.
Tacere Therapeutics is a Benitec Biopharma company.
http://www.tacerebio.com/index.htm
